Alvotech acquires Xbrane’s R&D operations and the biosimilar candidate XB003. Xbrane retains some pre-clinical development programs, that it intends to commercialize, and will continue operating as a ...

The Paramedic Chiefs of Canada (PCC) are calling on the federal government to immediately exempt ambulances and their key life-saving medical equipment from the proposed counter-tariffs in response to ...

Northern Karelia Cooperative Society (PKO), a customer members owned cooperative, has chosen the Aino SaaS platform as part of an initiative to enhance workforce well-being and improve work ability ...

DATA PROTECTION BioPorto A/S will as part of your communication and interaction with you collect and process personal data about you. You can read more about our privacy notice at ...

LOS ANGELES, March 19, 2025 (GLOBE NEWSWIRE) -- Comprehensive Urology launches its new observational study, TEM-C for Chronic ...

Financial Considerations Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate Dren-0201 for an upfront payment of $600 million and ...

Sequana Medical to Sponsor Liver Connect, 5th Annual Conference of Chronic Liver Disease Foundation ...

Updated mid-term outlook: 2024-28 revenue CAGR of 5-7% with c.10% REBIT margin by 2028; and 2025 guidance: REBIT of at least EUR 25 million supported by improved performance predictability linked to ...

The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other ...

The shares are being offered by Akebia pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (“SEC”) on September 3, 2024 and declared effective by the ...

Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive merger agreement under which Paratek will acquire Optinose, including its approved product ...

The potential delay in filing has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. The Company plans to file its Form 20-F as soon as practicable; however ...